Jove
Visualize
Contact Us

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estrogen receptor α (<i>Esr1</i>) mediates estrogen's ability to promote papillomavirus-induced cutaneous disease in male and female mice.

mBio·2026
Same author

Integrated Single-Cell and Spatial Analysis Reveals Context-Dependent Myeloid-T Cell Interactions in Response to Immune Checkpoint Blockade in Head and Neck Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

<i>Mus musculus</i> papillomavirus MmuPV1 resists restriction by human APOBEC3B.

Journal of virology·2026
Same author

Mouse Vocal Fold Permeability In Vivo: Effects of Novel Low-Tech Injury and Instillation Methods.

The Laryngoscope·2025
Same author

<i>Mus Musculus</i> papillomavirus MmuPV1 resists restriction by human APOBEC3B.

bioRxiv : the preprint server for biology·2025
Same author

Identification and Characterization of MmuPV1 Causing Papillomatosis Outbreak in an Animal Research Facility.

Viruses·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Aug 5, 2025

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
10:28

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

8.4K

Drugs That Mimic Hypoxia Selectively Target EBV-Positive Gastric Cancer Cells.

Blue-Leaf A Cordes1, Andrea Bilger1, Richard J Kraus1

  • 1McArdle Laboratory for Cancer Research, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA.

Cancers
|March 29, 2023
PubMed
Summary

Iron chelators like Deferoxamine and Deferasirox preferentially kill Epstein-Barr virus-positive gastric cancer cells in vitro by inducing viral reactivation. However, their in vivo efficacy in promoting EBV reactivation is limited compared to gemcitabine.

Keywords:
EBVdeferasiroxdeferoxaminegastric cancerlytic-induction therapy

More Related Videos

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

973
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.0K

Related Experiment Videos

Last Updated: Aug 5, 2025

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
10:28

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

8.4K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

973
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.0K

Area of Science:

  • Oncology
  • Virology
  • Molecular Biology

Background:

  • Latent Epstein-Barr virus (EBV) infection is linked to various cancers, including 10% of gastric carcinomas.
  • Hypoxia-inducible factor-1α (HIF-1α) plays a role in switching EBV from a latent to a lytic state.
  • Previous research identified HIF-1α-stabilizing drugs capable of inducing EBV reactivation.

Purpose of the Study:

  • To evaluate the efficacy of HIF-1α-stabilizing drugs in selectively eliminating EBV-positive gastric cancer cells.
  • To compare the in vitro and in vivo effectiveness of iron chelators and other drug classes in inducing EBV reactivation.

Main Methods:

  • Testing iron chelators (Deferoxamine, Deferasirox), a prolyl hydroxylase inhibitor (Molidustat), and a neddylation inhibitor (Pevonedistat) on EBV-positive (AGS-Akata, AGS-BDneo, SNU-719) and EBV-negative (AGS) gastric cancer cell lines.
  • Assessing preferential cell killing and EBV lytic reactivation.
  • Evaluating drug efficacy in EBV-infected AGS-Akata xenografts in NSG mice.

Main Results:

  • Iron chelators (Deferoxamine, Deferasirox) and Molidustat demonstrated preferential killing of EBV-positive gastric cancer cells.
  • Deferoxamine and Deferasirox induced EBV lytic reactivation in vitro in a subset of cells, with enhanced effects when combined with ganciclovir.
  • In vivo studies showed limited induction of lytic EBV protein synthesis by Deferoxamine and Deferasirox in xenografts compared to gemcitabine.

Conclusions:

  • FDA-approved iron chelators show promise for selectively targeting EBV-positive gastric cancer cells in vitro.
  • While effective in vitro, iron chelators exhibit lower in vivo efficacy in promoting EBV reactivation compared to gemcitabine.
  • Further research is needed to optimize therapeutic strategies for EBV-associated gastric cancers.